瑞舒伐他汀治疗精神分裂症患者高LDL-C血症的疗效研究

目的 探讨瑞舒伐他汀对精神分裂症伴高低密度脂蛋白胆固醇（LDL-C）血症患者的疗效及安全性.方法 选取64例精神分裂症伴高LDL-C血症患者随机分为两组,分别接受抗精神病药物合并瑞舒伐他汀治疗（研究组31例）和单纯抗精神病药物治疗（对照组33例）,于入组前及治疗后第4、8周末应用阳性和阴性综合征量表（PANSS）、治疗中需处理的不良反应症状量表（TESS）评定患者的精神症状和不良反应情况,入组时及治疗后第2、4、6、8周末进行LDL-C、空腹血糖、腰围、体质量的测量,评定患者的代谢指标变化.结果 治疗后第8周末研究组PANSS阴性症状因子分与入组时比较显著降低（P＜0.05）.治疗后第8周末研究组体质量、腰围、LDL-C与入组时比较显著降低（P＜0.01）;两组间比较,治疗后第6、8周末研究组LDL-C显著低于对照组（P＜0.05,P＜0.01）;治疗后第8周末研究组体质量、腰围显著低于对照组（P＜0.01）.结论 瑞舒伐他汀能改善精神分裂症伴高LDL-C血症患者的代谢指标且不良反应少.

The effect of rosuvastatin on hyper-LDL cholesterolemia in patients with schizophrenia

Objective To investigate the effect of rosuvastatin on hyper-LDL cholesterolemia in schizophrenic patients. Methods 64 schizophrenics with hyper-LDL cholesterolemia were randomly divided into study group （ n = 31 ） treated with antipsychotics plus rosuvastatin and control group （n = 33） treated with antipsychotics for 8 weeks. All patients were assessed with Positive and Negative Syndrome Scale （PANSS） and Treatment Emergent Symptom Scale （TESS） at baseline and at the end of the 4th, 8th week of the treatment to evaluate the efficacy and side effects. Metabolic indexes including level of LDL- cholesterol （LDL-C）, fasting blood sugar, waist circumference and body mass were measured at the baseline and at the end of the 2nd, 4th, 6th, 8th week. Results Compared with the baseline, negative factor score of PANSS in study group decreased significantly （P 〈 0.05）, body mass, waist circumference and level of LDL-C in study group decreased significantly （ P 〈 0.05 ）. Level of LDL-C in study group was significantly lower than that in control group at the end of the 6th, 8th week of the treatment （P 〈0.05 and P 〈 0.01, respectively）. Body mass and waist circumference in study group were significantly lower than those in control group at the end of the 8-week treatment （P 〈 0.01 ）. Conclusion Rosuvastatin can effectively improve metabolic indexes in schizophrenic patients with hyper-LDL cholesterolemia.